After decades of rising opioid deaths, 2024 brought a sharp reversal

The decline did not arrive without warning. Federal data show smaller drops in 2018 (down 4 percent) and 2023 (down 3 percent), but neither approached the scale of what happened in 2024.

To understand the scope of the change, it helps to look at the long arc that preceded it.

The American opioid epidemic was declared a public-health emergency in 2017. By the end of 2024, it had claimed more than 860,000 lives over the prior twenty-five years. What started as a crisis driven by prescription opioids and heroin has, in recent years, been dominated by illicit synthetic fentanyl - a substance the CDC describes as roughly a hundred times more potent than morphine.

The American opioid epidemic has unfolded in three waves, according to a CDC framework adopted in 2018.

The first wave began in the late 1990s, when prescription opioids - drugs including OxyContin, Vicodin, and oxycodone - were marketed for chronic pain management. The rate of opioid prescribing in the United States nearly quadrupled between 1999 and 2010, according to the CDC. Deaths followed the prescriptions.

A separate spike, less often discussed, occurred during the same period: deaths involving methadone - another opioid widely prescribed for pain in the early 2000s - climbed to roughly 5,500 in 2007 before falling sharply as the medication's use shifted toward addiction treatment. Methadone now accounts for fewer than 4,000 American deaths a year.

The second wave began around 2010. Reformulations of OxyContin and crackdowns on so-called pill mills closed off the legal supply for many people who had become dependent on prescription opioids. Many of those people moved to heroin, which was cheaper and increasingly available. Heroin deaths more than tripled between 2010 and 2014.

The third wave began around 2013, when illicitly manufactured fentanyl entered the American drug supply, first as an adulterant in heroin, then in counterfeit pills, then as the supply itself. By 2016, synthetic opioids had overtaken every other category as the leading driver of overdose deaths. Fentanyl-involved deaths reached a peak of about 73,800 in 2022 and 2023, then fell to 47,735 in 2024.

Each wave changed under pressure from policy, enforcement and shifts in the drug supply. But each retreat was followed by a more potent substance.

The geography of the epidemic moved with the substance.

The first wave concentrated in Appalachia and parts of the Mountain West. By 2004, West Virginia had the highest opioid death rate in the country, a position the state held, with brief exceptions, for most of the next two decades. The second wave moved into the Northeast and Midwest. The heroin supply followed interstate corridors out of the Appalachian basin into Ohio, Pennsylvania, and New England.

"It's rare to find people who only overdose on cocaine or who only overdose on methamphetamines. Fentanyl is being used to lace the illicit drug market because it's very profitable."

— Dr. Nora Volkow, director of the National Institute on Drug Abuse

The third wave reached different regions at different times. New England saw fentanyl arrive first; New Hampshire's opioid death rate jumped sharply in 2015. The Pacific Northwest and Alaska saw fentanyl arrive last, an unevenness that public-health researchers say is now visible in the recovery.

The 2024 drop was not a single national event. It was fifty different events with different shapes.

Every state and the District of Columbia recorded a lower opioid death rate in 2024 than in 2023, according to CDC data. The states with the largest declines were generally those that had been hit hardest the longest. West Virginia's rate fell from 71.6 per 100,000 in 2023 to 38.6 in 2024, a 46 percent decline - the steepest in the country. Virginia and Wisconsin each fell 44 percent.

"This is the most dramatic improvement we have seen really since the opioid crisis began in the 1990s. A 27 percent drop in deaths, it's unprecedented."

— Brian Mann, NPR addiction correspondent, May 2025

The picture changes when the comparison year is moved to 2019, before the pandemic surge. Measured against pre-pandemic levels, 31 states still have higher opioid death rates than they did in 2019. Alaska's 2024 rate is more than triple its 2019 figure. Oregon and Washington are roughly three times as high.

The decline was not distributed equally across the populations inside it

Looking back to 2019, only one demographic group has a lower opioid overdose death rate than before the pandemic. Adults aged 18 to 25 fell from 13.3 deaths per 100,000 to 9.3 - a 30 percent decline, the steepest of any age group. White Americans, who had been the demographic most affected by the prescription-opioid wave of the 2000s, fell modestly, from 19.2 to 17.5.

The picture for almost every other group is some variation of the same trend in reverse. American Indian and Alaska Native people had the highest opioid death rate of any racial or ethnic group in 2024, at 35.5 per 100,000 - roughly double their 2019 figure of 17.7. Black Americans saw their rate rise from 17.3 to 22.8 over the same period, a 32 percent increase.

Older adults are also worse off than before the pandemic. The death rate among adults 65 and older has risen by more than 60 percent since 2019, climbing from 4.3 per 100,000 to 7.0. Researchers studying the post-pandemic decline have suggested the slower recovery in this group may reflect that substance use disorder is harder to detect in older patients, and that few treatment programs are designed for their needs.

The CDC has cited five overlapping factors in the 2024 decline: expanded access to naloxone; harm-reduction programs including fentanyl test strips and syringe services; improved access to medications for opioid use disorder; law enforcement efforts targeting fentanyl trafficking; and shifts in the illicit drug supply.

A 2025 preprint posted to medRxiv argued that decreased fentanyl potency, documented in Drug Enforcement Administration seizure data, was the primary driver. Other researchers, including those at the Vital Strategies public health organization, have argued that expanded harm-reduction infrastructure deserves more credit. The CDC, in its official statements, has declined to differentiate the relative contributions.

A separate factor, less often cited in public statements but documented in the academic literature, is the size of the population at risk. A 2025 study published in The Lancet Regional Health Americas estimated that 109,783 additional opioid overdose deaths would have occurred between 2016 and 2023 had the at-risk population not declined.

The decline is also fragile. Proposed reductions in federal harm-reduction funding could weaken some of the infrastructure researchers credit with saving lives. At the same time, the administration's redesignation of illicit fentanyl as a "weapon of mass destruction" signals a more enforcement-focused response. New synthetic opioids, including nitazenes - which the DEA has reported can be ten times more potent than fentanyl - have begun to appear in seizure data.

For now, federal data show the wave receding. Provisional 2025 figures suggest the decline is continuing, though more slowly. Whether 2024 marks the beginning of a sustained reversal will become clearer when 2025 data are finalized in late 2026.